Health is a state of complete physical, mental, and social well-being (WHO definition), not merely the absence of disease. It can be influenced by genetic disorders, infections, lifestyle (diet, exercise, stress), and environmental factors.
Bacterial diseases: Typhoid (Salmonella typhi — Widal test), Pneumonia (Streptococcus pneumoniae and Haemophilus influenzae — alveoli fill with fluid), Plague (Yersinia pestis), Diphtheria (Corynebacterium diphtheriae), Tetanus (Clostridium tetani), Cholera (Vibrio cholerae — rice-water stools), TB (Mycobacterium tuberculosis).
Viral diseases: Common cold (Rhinovirus), Influenza (Orthomyxovirus), AIDS (HIV), Dengue (Flavivirus — Aedes mosquito), Chikungunya (Togavirus — Aedes), COVID-19 (SARS-CoV-2), Hepatitis B (Hepadnavirus), Rabies (Rhabdovirus — infected animal bite), Polio (Enterovirus — now eradicated in most countries).
Protozoan diseases: Malaria (Plasmodium vivax/falciparum/malariae/ovale — transmitted by female Anopheles mosquito), Amoebic dysentery (Entamoeba histolytica), Kala-azar/Leishmaniasis (Leishmania donovani — sandfly), Sleeping sickness (Trypanosoma gambiense — tsetse fly).
Fungal diseases: Ringworm (Trichophyton, Microsporum, Epidermophyton), Candidiasis (Candida albicans).
Helminthic diseases: Ascariasis (Ascaris lumbricoides — roundworm), Filariasis/Elephantiasis (Wuchereria bancrofti — mosquito), Tapeworm infection (Taenia solium — pork).
The body's ability to recognise and defend against pathogens. Two types: Innate (non-specific) — present from birth, not pathogen-specific. Components: Physical barriers (skin, mucous membranes), Physiological barriers (stomach acid HCl, lysozyme in tears, saliva), Cellular barriers (phagocytes — neutrophils, macrophages, NK cells), Cytokine barriers (interferons — protect against viral infections). Acquired (specific) — develops after exposure to a pathogen. Attributes: Specificity, Diversity, Memory (faster and stronger response on second exposure — immunological memory).
Humoral immunity: B-lymphocytes produce antibodies (immunoglobulins) that circulate in blood and lymph. Antibody structure: 4 polypeptide chains (2 heavy + 2 light) forming a Y-shape. There are 5 classes: IgG (most abundant, crosses placenta — provides passive immunity to foetus), IgA (present in secretions — colostrum, saliva, tears), IgM (first antibody produced in primary response), IgE (involved in allergic reactions), IgD (B-cell receptor). Cell-mediated immunity: T-lymphocytes directly attack infected cells. Types: Helper T cells (TH) (activate B cells and other T cells), Cytotoxic T cells (TC) (kill infected cells), Suppressor T cells (Ts) (regulate immune response).
A vaccine contains weakened/dead pathogens or antigens that stimulate the immune system to produce memory cells. On subsequent exposure, the response is rapid and strong. Edward Jenner (1796) developed the first vaccine for smallpox using cowpox virus. Smallpox has been eradicated globally (WHO, 1979). The Expanded Programme on Immunisation (EPI) includes vaccines for TB (BCG), Polio (OPV/IPV), Diphtheria-Pertussis-Tetanus (DPT), Measles, MMR, Hepatitis B, and more.
| Feature | Active Immunity | Passive Immunity |
|---|---|---|
| Antibody source | Produced by the body itself | Received from outside |
| Immune response | Yes — B and T cells are activated | No — ready-made antibodies are given |
| Memory | Immunological memory is formed | No memory — temporary protection |
| Duration | Long-lasting (years to lifetime) | Short-term (weeks to months) |
| Onset | Slow (takes days to weeks) | Immediate |
| Natural examples | Infection → recovery | Maternal antibodies (IgG via placenta, IgA via colostrum) |
| Artificial examples | Vaccination | Antibody injection (anti-venom, anti-tetanus serum) |
The lymphatic system plays a crucial role in immunity. Lymph is the fluid that leaks from blood capillaries into intercellular spaces. It contains WBCs (especially lymphocytes) and is circulated through lymphatic vessels. Primary lymphoid organs: Bone marrow (B-lymphocytes mature here) and Thymus gland (T-lymphocytes mature here — located behind the sternum, largest in infants, atrophies with age). Secondary lymphoid organs: Lymph nodes (filter lymph, contain B and T cells), Spleen (filters blood, contains lymphocytes and macrophages — the graveyard of RBCs), Tonsils (protect respiratory tract), Peyer's patches (in the small intestine — protect gut), Appendix (vestigial but contains lymphoid tissue). Mucosa-Associated Lymphoid Tissue (MALT) — located in respiratory, digestive, and urogenital tracts forming the first line of defence at mucosal surfaces.
Allergy: Exaggerated (hypersensitive) immune response to harmless environmental substances called allergens (pollen, dust mites, pet dander, certain foods, drugs). Mechanism: First exposure → allergens sensitise mast cells (IgE binds to FcεRI receptors). Subsequent exposure → allergen cross-links IgE on mast cells → mast cells degranulate → release histamine, leukotrienes, prostaglandins → vasodilation, bronchoconstriction, increased mucus, itching. Symptoms: sneezing, runny nose, watery eyes, rashes (urticaria), asthma, anaphylaxis (severe, life-threatening). Diagnosis: Skin prick test, serum IgE levels. Treatment: Antihistamines (block histamine H1 receptors — cetirizine, loratadine), corticosteroids, epinephrine (adrenaline — for anaphylaxis), immunotherapy (allergy shots — desensitisation).
Autoimmune diseases: The immune system mistakenly attacks self-antigens (failure of self-tolerance). Causes include genetic predisposition (HLA associations) and environmental triggers (infection, stress). Examples: Rheumatoid arthritis (autoantibodies against joint synovia — RF factor), Type 1 diabetes (T cells destroy pancreatic β-cells), Multiple sclerosis (T cells attack myelin sheath of neurons), Systemic Lupus Erythematosus (SLE — autoantibodies against DNA, nuclear antigens — butterfly rash on face), Graves' disease (autoantibodies stimulate TSH receptor on thyroid → hyperthyroidism), Hashimoto's thyroiditis (autoantibodies against thyroid → hypothyroidism), Myasthenia gravis (autoantibodies block acetylcholine receptors at neuromuscular junction → muscle weakness).
Severe Combined Immunodeficiency (SCID): A group of rare genetic disorders with absence of both B and T cell function (combined humoral and cell-mediated deficiency). Most severe form is X-linked SCID (mutation in IL2RG gene encoding the common gamma chain of cytokine receptors). "Bubble boy" disease — patients must live in sterile environments. Treatment: bone marrow transplantation, gene therapy (first successful human gene therapy was for ADA-SCID in 1990). Without treatment, death occurs within the first year from severe infections.
DiGeorge Syndrome (22q11.2 deletion syndrome): Microdeletion on chromosome 22. Results in thymic aplasia/hypoplasia (absent/underdeveloped thymus) → T-cell deficiency. Associated with cardiac abnormalities, characteristic facial features, cleft palate. Treatment: thymus transplantation, supportive care.
Chediak-Higashi Syndrome: Autosomal recessive disorder (LYST gene mutation). Defective phagocytosis due to abnormal lysosomal trafficking — neutrophils have giant granules that cannot fuse with phagosomes. Recurrent pyogenic infections, albinism (partial), peripheral neuropathy. Treatment: bone marrow transplant.
Chronic Granulomatous Disease (CGD): X-linked (most common) or autosomal recessive. Defect in NADPH oxidase enzyme complex in phagocytes → inability to produce ROS to kill engulfed bacteria. Recurrent infections with catalase-positive organisms (Staphylococcus aureus, Serratia, Aspergillus). Granuloma formation in various organs. Diagnosis: Nitroblue Tetrazolium (NBT) test — fails to turn blue (negative). Treatment: IFN-γ therapy, prophylactic antibiotics, BMT, gene therapy.
Hyper-IgE Syndrome (Job Syndrome): Autosomal dominant (STAT3 mutation). Extremely high serum IgE (>2000 IU/mL), recurrent staphylococcal skin abscesses ("cold abscesses" — lack classical inflammation), pneumonia with pneumatocele formation, eczema, retained primary teeth, skeletal abnormalities. Treatment: prophylactic antibiotics, antifungals.
| Disorder | Defect | Affected Cells | Key Features | Treatment |
|---|---|---|---|---|
| SCID | IL2RG, ADA deficiency | B & T cells | Absent B and T cell function, severe infections in infancy, "bubble boy" | BMT, gene therapy |
| DiGeorge Syndrome | 22q11.2 deletion | T cells (thymic aplasia) | T-cell deficiency, cardiac defects, facial abnormalities, cleft palate | Thymus transplant |
| Chediak-Higashi | LYST mutation | Neutrophils | Giant lysosomal granules, defective phagocytosis, albinism, infections | BMT |
| CGD | NADPH oxidase defect | Phagocytes | No ROS, catalase+ infections, granulomas, NBT test negative | IFN-γ, antibiotics, BMT |
| Hyper-IgE (Job) | STAT3 mutation | Neutrophils, T cells | High IgE, cold abscesses, eczema, pneumatoceles, retained teeth | Prophylactic antibiotics |
Caused by HIV (Human Immunodeficiency Virus) — a retrovirus (RNA virus with reverse transcriptase). HIV infects and destroys Helper T cells (CD4+ T cells), weakening the immune system. Transmission: Sexual contact (most common), Blood transfusion, Sharing needles, Mother-to-child (vertical transmission). Not transmitted: Handshake, sharing utensils, mosquito bites, hugging. Symptoms: Flu-like initial stage (2-6 weeks), asymptomatic latency (8-10 years), then AIDS (opportunistic infections — TB, Pneumocystis pneumonia, Kaposi's sarcoma, dementia). Diagnosis: ELISA (screening), Western blot (confirmatory). Treatment: HAART (Highly Active Antiretroviral Therapy) — combination of drugs including Reverse transcriptase inhibitors (AZT, nevirapine), Protease inhibitors, Integrase inhibitors. No cure yet, but can be managed. Prevention: Safe sex (condoms), sterile needles, blood screening, awareness through NACO and WHO programmes.
| Feature | Innate (Non-Specific) | Acquired (Specific) |
|---|---|---|
| Presence | Present from birth | Develops after exposure |
| Specificity | Non-specific — defends against all pathogens | Highly specific — targets specific antigens |
| Memory | No immunological memory | Yes — faster response on re-exposure |
| Response time | Immediate (0-4 hours) | Slow (days for primary response) |
| Components | Physical, physiological, cellular, cytokine barriers | B-lymphocytes (humoral), T-lymphocytes (cell-mediated) |
| Cell types | Neutrophils, macrophages, NK cells, dendritic cells | B cells, T cells (helper, cytotoxic, regulatory) |
| Inheritance | Hereditary — passed from parents | Not hereditary — acquired during lifetime |
The complement system is a group of ~30 serum proteins that enhance (complement) the ability of antibodies and phagocytes to clear pathogens. It is activated by three pathways: Classical (antibody-dependent), Alternative (spontaneous activation on pathogen surfaces), and Lectin pathway (mannose-binding lectin binds to bacterial carbohydrates). Functions include: opsonisation (coating pathogens for phagocytosis), chemotaxis (attracting immune cells), lysis (forming membrane attack complex that punches holes in bacterial cell walls), and inflammation (triggering mast cell degranulation). Interferons are cytokines (signalling proteins) released by virus-infected cells. They are part of the innate immune system (cytokine barrier). Interferons signal neighbouring uninfected cells to produce antiviral proteins that inhibit viral replication. They also activate NK cells and macrophages. Types: IFN-α (leukocytes), IFN-β (fibroblasts), IFN-γ (T cells and NK cells). Interferon therapy is used in the treatment of hepatitis B, hepatitis C, multiple sclerosis, and certain cancers. Interferons were discovered by Isaacs and Lindenmann (1957).
Monoclonal antibodies are identical antibodies produced by a single clone of B-lymphocytes that recognise the same specific epitope on an antigen. They are produced using hybridoma technology, developed by K—hler and Milstein (1975, Nobel Prize 1984).
Production (Hybridoma Technology): (1) A mouse is immunised with a specific antigen. (2) B-lymphocytes producing antibodies against the antigen are isolated from the mouse's spleen. (3) These B cells are fused with myeloma cells (immortalised plasma cell tumour cells) using polyethylene glycol (PEG) or electrical fusion. (4) The fused cells (hybridomas) are cultured in HAT medium (Hypoxanthine-Aminopterin-Thymidine) — unfused B cells die (short-lived), unfused myeloma cells die (HGPRT-deficient, killed by aminopterin). Only hybridomas survive. (5) Hybridomas are screened for desired antibody production and cloned. (6) Selected clones produce large quantities of monoclonal antibodies. mAbs can be chimeric (mouse variable + human constant) or humanised (only CDRs from mouse) to reduce immunogenicity.
Applications: (1) Diagnosis — ELISA tests, pregnancy tests (detect hCG), blood typing, detection of hormones and pathogens. (2) Therapy — Cancer (rituximab for B-cell lymphomas, trastuzumab/Herceptin for HER2+ breast cancer), autoimmune diseases (infliximab for RA), transplant rejection (muromonab-CD3, basiliximab), infectious diseases (palivizumab for RSV), cardiovascular (abciximab). (3) Targeted drug delivery — antibody-drug conjugates (ADCs) like trastuzumab emtansine. (4) Immunoassay — pregnancy test uses mAbs against hCG. When hCG in urine binds to immobilised anti-hCG antibodies coloured with gold particles, a visible line appears.
Examples of therapeutic mAbs: Rituximab (anti-CD20 — B-cell lymphoma, RA), Trastuzumab (anti-HER2 — breast cancer), Infliximab (anti-TNF-α — RA, Crohn's), Adalimumab (anti-TNF-α — RA, psoriasis), Bevacizumab (anti-VEGF — colorectal cancer, inhibits angiogenesis), Pembrolizumab (anti-PD-1 — checkpoint inhibitor). mAb naming suffixes: -omab = mouse, -ximab = chimeric, -zumab = humanised, -umab = fully human.
| mAb (Brand) | Target | Disease | Type |
|---|---|---|---|
| Rituximab (Rituxan) | CD20 on B cells | Non-Hodgkin lymphoma, RA | Chimeric |
| Trastuzumab (Herceptin) | HER2 receptor | HER2+ breast cancer | Humanised |
| Infliximab (Remicade) | TNF-α | RA, Crohn's disease | Chimeric |
| Bevacizumab (Avastin) | VEGF | Colorectal cancer | Humanised |
| Pembrolizumab (Keytruda) | PD-1 | Multiple cancers | Humanised |
| Abciximab (ReoPro) | GPIIb/IIIa | Angioplasty (anti-clot) | Chimeric |
| Palivizumab (Synagis) | RSV F protein | RSV prophylaxis in infants | Humanised |
ELISA is a sensitive immunological test to detect and quantify antigens or antibodies using enzyme-labelled reagents. The enzyme converts a colourless substrate to a coloured product, measured spectrophotometrically. Developed by Engvall and Perlmann (1971).
Principle: An antigen-antibody reaction is detected by an enzyme conjugated to one reactant. The enzyme catalyses a substrate reaction producing a measurable colour change — intensity proportional to the amount of antigen/antibody.
Types of ELISA:
Direct ELISA: Antigen is immobilised on a microtitre plate. Enzyme-labelled primary antibody binds directly to the antigen. Colour proportional to antigen. Used to detect antigen in sample.
Indirect ELISA: Antigen is immobilised. Unlabelled primary antibody (patient serum) binds. Enzyme-labelled secondary antibody (anti-human IgG) binds the primary. Colour proportional to primary antibody present. Used for HIV screening — detects anti-HIV antibodies in patient serum.
Sandwich ELISA: Capture antibody is immobilised. Sample antigen binds to capture antibody. Enzyme-labelled detection antibody (against a different epitope) binds the captured antigen. Highly specific (two antibodies, two epitopes). Used for pregnancy test (hCG), cytokines.
Competitive ELISA: Antigen in sample competes with labelled antigen for limited antibody. More antigen → less labelled antigen binds → weaker colour. Inverse relationship. Used for small molecules (haptens, drugs, hormones).
Steps in Indirect ELISA (HIV diagnosis): (1) Coating: HIV antigens adsorbed onto microtitre wells. (2) Blocking: Unbound sites blocked with BSA to prevent non-specific binding. (3) Washing: Remove excess blocking agent. (4) Primary antibody: Patient serum added — anti-HIV antibodies bind immobilised antigens. (5) Washing: Unbound antibodies removed. (6) Secondary antibody: Enzyme-labelled anti-human IgG added — binds patient antibodies. (7) Washing: Unbound conjugate removed. (8) Substrate: Enzyme substrate (TMB for HRP) added — colour develops if positive (blue → yellow on stop). (9) Reading: Absorbance at 450 nm. ELISA is a screening test for HIV — positive results confirmed by Western blot.
Applications: HIV screening (indirect ELISA), Pregnancy test (sandwich ELISA for hCG), Food allergen detection, Drug monitoring, Hormone assays (thyroid, cortisol), Autoantibody detection (ANA in SLE), Plant virus detection, GMO detection, Cytokine measurement. ELISA is highly sensitive (picogram to nanogram quantities), quantitative, and automatable.
| Type | Immobilised | Detected | Signal vs Analyte | Typical Application |
|---|---|---|---|---|
| Direct ELISA | Antigen (sample) | Antigen | Directly proportional | Large antigen detection |
| Indirect ELISA | Antigen (known) | Antibody in serum | Directly proportional | HIV screening, antibody detection |
| Sandwich ELISA | Capture antibody | Antigen | Directly proportional | hCG (pregnancy), cytokines, hormones |
| Competitive ELISA | Antibody (or antigen) | Small antigens/haptens | Inversely proportional | Drug monitoring, steroid hormones |
| Vaccine | Disease | Type | Schedule (as per National Immunisation Schedule) |
|---|---|---|---|
| BCG | Tuberculosis | Live attenuated | At birth (or as soon as possible till 1 year) |
| OPV (Oral Polio Vaccine) | Poliomyelitis | Live attenuated (oral) | At birth, 6, 10, 14 weeks + booster at 16-24 months |
| IPV (Inactivated Polio Vaccine) | Poliomyelitis | Inactivated (injected) | At 6 and 14 weeks |
| DPT (Diphtheria, Pertussis, Tetanus) | Diphtheria, Whooping cough, Tetanus | Toxoid/Inactivated | 6, 10, 14 weeks + boosters at 16-24 months and 5-6 years |
| Measles vaccine | Measles | Live attenuated | 9-12 months + booster at 16-24 months (MMR) |
| MMR (Measles, Mumps, Rubella) | Measles, Mumps, Rubella | Live attenuated | 9-12 months + booster at 16-24 months |
| Hepatitis B | Hepatitis B | Recombinant | At birth (within 24 hours), 6, 10, 14 weeks |
| TT (Tetanus Toxoid) | Tetanus | Toxoid | 10 years + 2 doses for pregnant women |
| Hib (Haemophilus influenzae type b) | Meningitis, Pneumonia | Conjugate | 6, 10, 14 weeks |
| Rotavirus | Diarrhoea (Rotavirus) | Live attenuated | 6, 10, 14 weeks (oral) |
| PCV (Pneumococcal Conjugate) | Pneumonia | Conjugate | 6, 14 weeks + booster at 9 months |
Vaccines work by exposing the immune system to an antigen in a safe form, generating immunological memory. Different vaccine platforms use different strategies to present antigens to the immune system:
Live Attenuated Vaccines: Contain a weakened (attenuated) form of the live pathogen that cannot cause disease in immunocompetent individuals. Attenuation is achieved by passaging the pathogen through non-human cells or animals until it loses virulence genes. Mechanism: The vaccine strain replicates in the host (limited replication), stimulating both humoral and cell-mediated immunity without causing disease. Advantages: Strong, long-lasting immunity (often lifelong with 1-2 doses), activates both B and T cells. Disadvantages: Cannot be given to immunocompromised individuals, requires cold chain, risk of reversion to virulence (very rare). Examples: BCG (TB), OPV (polio), MMR (measles, mumps, rubella), Rotavirus, Yellow fever, Varicella (chickenpox).
Inactivated/Killed Vaccines: Contain whole pathogens killed by heat, chemicals (formaldehyde, β-propiolactone), or radiation. Mechanism: The inactivated pathogen cannot replicate but intact surface antigens are still recognised. Primarily elicits humoral immunity (antibody response). Advantages: Safe for immunocompromised individuals, cannot revert to virulence, more stable. Disadvantages: Weaker immune response — requires multiple doses (3-4) and boosters, mainly antibody-mediated. Examples: IPV (polio), Rabies, Hepatitis A, Influenza (injected), Pertussis (whole-cell).
Toxoid Vaccines: Contain inactivated toxins (toxoids) produced by bacteria. Treated with formaldehyde to destroy toxicity while retaining immunogenicity. Mechanism: Immune system produces antitoxin antibodies that neutralise the bacterial toxin. Advantages: Safe, stable, induces strong antibody response. Disadvantages: Requires boosters, weak cellular immunity. Examples: Diphtheria toxoid (DPT), Tetanus toxoid (TT).
Recombinant/Subunit Vaccines: Contain specific antigens produced by genetic engineering. Mechanism: Only the immunogenic component is presented — no infectious material. Advantages: Very safe, can be given to immunocompromised, precisely defined, fewer side effects. Disadvantages: Requires adjuvants, often needs multiple doses. Examples: Hepatitis B (HBsAg in yeast), HPV (virus-like particles — Gardasil, Cervarix), Acellular pertussis.
Conjugate Vaccines: Polysaccharide antigens linked to a carrier protein to make them immunogenic in infants. Mechanism: Pure polysaccharides are T-independent antigens — weak response without memory in children under 2. Conjugation to a carrier protein (tetanus toxoid, CRM197) makes them T-dependent, generating strong antibody responses and memory. Advantages: Protective in infants, induces memory, herd immunity. Examples: Hib, PCV13 (pneumococcal), MenACWY (meningococcal), Typhoid conjugate vaccine.
mRNA Vaccines: Contain synthetic mRNA encoding the target antigen, encapsulated in lipid nanoparticles. Mechanism: mRNA is taken up by host cells and translated into antigen protein by host ribosomes. The antigen is presented on MHC molecules, stimulating both humoral and cell-mediated immunity. mRNA does not enter the nucleus or integrate into host genome. Advantages: Rapid development and manufacturing, safe, induces both B and T cell responses. Disadvantages: Requires ultra-cold storage (-20°C to -80°C), reactogenicity. Examples: Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccines.
Viral Vector Vaccines: Use a harmless virus (adenovirus, modified vaccinia Ankara) as a vector to deliver genetic material encoding the target antigen. Mechanism: The viral vector enters host cells and expresses the target antigen. Antigen is presented on MHC molecules, stimulating strong T cell and antibody responses. The vector is replication-defective. Advantages: Strong cellular and humoral immunity, single dose may suffice, stable at fridge temperatures (some). Disadvantages: Pre-existing immunity to vector can reduce efficacy. Examples: Oxford-AstraZeneca (ChAdOx1-S), Johnson & Johnson (Ad26.COV2.S) for COVID-19; Ervebo (Ebola — VSV vector).
| Vaccine Type | Content | Immune Response | Doses Required | Examples |
|---|---|---|---|---|
| Live Attenuated | Live, weakened pathogen | Humoral + Cellular (strong) | 1-2 | BCG, OPV, MMR, Rotavirus |
| Inactivated/Killed | Dead pathogen | Primarily humoral (moderate) | 3-4 + boosters | IPV, Rabies, Hepatitis A |
| Toxoid | Inactivated toxin | Humoral (antitoxin) | 3 + boosters | DPT, TT |
| Recombinant/Subunit | Specific antigen(s) | Humoral + some cellular | 2-3 + booster | Hepatitis B, HPV |
| Conjugate | Polysaccharide + carrier protein | Humoral (T-dependent, strong) | 3-4 + booster | Hib, PCV13, MenACWY |
| mRNA | mRNA encoding antigen | Humoral + Cellular (strong) | 2 + boosters | Pfizer, Moderna COVID-19 |
| Viral Vector | Recombinant viral DNA | Humoral + Cellular (strong) | 1-2 | AstraZeneca, J&J, Ervebo |
Uncontrolled cell division caused by genetic mutations in oncogenes (promote cell division — when mutated, become hyperactive) and tumour suppressor genes (e.g., p53 — normally prevent cancer; when mutated, lose function). Cancer-causing genes (oncogenes) were discovered by Bishop and Varmus (Nobel Prize). Cancer results from accumulation of multiple mutations over time, not a single change.
| Feature | Benign Tumour | Malignant Tumour |
|---|---|---|
| Growth rate | Slow | Rapid |
| Invasiveness | Non-invasive (localised) | Invasive — invades surrounding tissues |
| Spread (metastasis) | Does not metastasise | Metastasises via blood/lymph to distant sites |
| Encapsulation | Encapsulated (well-defined boundary) | Not encapsulated (irregular boundary) |
| Cell morphology | Resembles normal cells | Anaplastic (abnormal, pleomorphic) |
| Recurrence | Rare after removal | Common — may recur after treatment |
| Danger to life | Rarely life-threatening | Life-threatening if untreated |
| Example | Uterine fibroids, skin moles | Lung carcinoma, breast cancer, leukaemia |
Carcinogens: Physical (UV, X-rays, gamma rays — ionising radiation damages DNA), Chemical (tobacco smoke containing benzopyrene, asbestos, aflatoxins from fungus on peanuts — potent liver carcinogens), Biological (oncogenic viruses — HPV causes cervical cancer, Hepatitis B and C cause liver cancer, EBV causes Burkitt's lymphoma). Diagnosis: Biopsy (tissue examination), CT/MRI scans, X-rays, mammography (breast cancer), Pap smear (cervical cancer), endoscopy, blood tests (tumour markers like PSA for prostate cancer). Treatment: Surgery (removal of tumour), Radiation therapy (radiotherapy — high-energy radiation kills cancer cells), Chemotherapy (drugs that target rapidly dividing cells — side effects: hair loss, nausea, immunosuppression), Immunotherapy (monoclonal antibodies like rituximab, checkpoint inhibitors like pembrolizumab), Targeted therapy (imatinib/Gleevec for Chronic Myeloid Leukaemia — targets BCR-ABL fusion protein). Cancer warning signs (CAUTION): Change in bowel/bladder habits, A sore that does not heal, Unusual bleeding/discharge, Thickening/lump in breast or elsewhere, Indigestion/difficulty swallowing, Obvious change in wart/mole, Nagging cough/hoarseness.
Cancer arises from the accumulation of mutations in two broad classes of genes: proto-oncogenes (which promote cell growth) and tumour suppressor genes (which inhibit cell growth). A single mutation is rarely sufficient — multiple "hits" are required (Knudson's two-hit hypothesis for retinoblastoma).
| Feature | Proto-oncogenes | Tumour Suppressor Genes |
|---|---|---|
| Normal function | Promote cell growth and division (growth factors, receptors, signal transducers, transcription factors) | Inhibit cell growth, repair DNA damage, induce apoptosis, regulate cell cycle checkpoints |
| Effect of mutation | Gain-of-function → activated oncogene → uncontrolled proliferation | Loss-of-function (both alleles mutated) → loss of growth inhibition |
| Inheritance pattern | Dominant at cellular level (one mutated allele sufficient) | Recessive at cellular level (both alleles must be mutated — "two-hit hypothesis") |
| Mechanism of activation | Point mutation (ras), Gene amplification (myc), Chromosomal translocation (BCR-ABL in CML) | Deletion, point mutation (loss of function), Epigenetic silencing (promoter methylation) |
| Examples | ras (GTPase — mutated in ~30% of cancers), myc (transcription factor — amplified in Burkitt's lymphoma), HER2/neu (receptor tyrosine kinase — amplified in breast cancer), BCR-ABL (fusion protein in CML), BRAF (kinase — mutated in melanoma) | p53/TP53 (guardian of the genome — mutated in >50% of cancers), Rb (retinoblastoma — cell cycle regulator), BRCA1/2 (DNA repair — breast/ovarian cancer), APC (colon cancer), PTEN (PI3K pathway inhibitor), VHL (von Hippel-Lindau) |
| Knudson's two-hit | Not applicable (single hit sufficient) | Both alleles must be inactivated (e.g., Rb gene — first hit inherited or somatic, second hit somatic) |
| Therapeutic targeting | Targeted inhibitors (imatinib for BCR-ABL, gefitinib for EGFR, vemurafenib for BRAF V600E, trastuzumab for HER2) | Harder to target — synthetic lethality approaches (PARP inhibitors for BRCA-mutated cancers) |
Cancer staging describes the extent of cancer spread. The most commonly used system is the TNM system (Tumour, Node, Metastasis): T describes the size of the primary tumour (T0-T4), N describes lymph node involvement (N0-N3), M describes distant metastasis (M0 or M1). Stage I: localised cancer. Stage II-III: locally advanced with lymph node involvement. Stage IV: metastatic cancer (spread to distant organs). Staging guides treatment decisions and predicts prognosis.
Cancer grading describes how much tumour cells resemble normal cells (differentiation). Grade 1 (well-differentiated) — cells look relatively normal, grow slowly, better prognosis. Grade 3 (poorly differentiated/anaplastic) — cells look abnormal, grow aggressively. Grade 4 (undifferentiated) — cells bear no resemblance to normal tissue.
Traditional chemotherapy targets all rapidly dividing cells, causing significant side effects. Targeted therapy uses drugs that specifically target molecular abnormalities in cancer cells:
Imatinib (Gleevec): The first successful targeted cancer drug. Targets the BCR-ABL fusion protein — a constitutively active tyrosine kinase produced by the Philadelphia chromosome (t(9;22) translocation) in Chronic Myeloid Leukaemia (CML). Imatinib binds to the ATP-binding pocket of BCR-ABL, inhibiting its activity. Treated CML patients have near-normal life expectancy. Also targets c-KIT (for GIST).
Gefitinib (Iressa) and Erlotinib (Tarceva): Target EGFR tyrosine kinase — mutated and overactive in some non-small cell lung cancers (EGFR-mutated NSCLC). These inhibitors block signalling pathways driving cancer cell proliferation.
Trastuzumab (Herceptin): A monoclonal antibody targeting HER2/neu receptor — overexpressed in ~20% of breast cancers (HER2-positive). Blocks receptor signalling and triggers antibody-dependent cell-mediated cytotoxicity (ADCC).
Vemurafenib: Targets the BRAF V600E mutation — found in ~50% of melanomas. BRAF is a kinase in the MAPK/ERK signalling pathway. The V600E mutation makes BRAF constitutively active.
Immunotherapy (Checkpoint Inhibitors): Cancer cells evade the immune system by expressing inhibitory molecules that turn off T cells. PD-1/PD-L1 pathway: Cancer cells express PD-L1 which binds to PD-1 on T cells, suppressing T cell activity. Anti-PD-1 antibodies (pembrolizumab/Keytruda, nivolumab/Opdivo) block this interaction, restoring T cell killing. Approved for melanoma, NSCLC, kidney cancer, Hodgkin lymphoma. CTLA-4 pathway: Ipilimumab (Yervoy) blocks CTLA-4 on T cells, enhancing T cell activation. Used for melanoma. Checkpoint inhibitors can cause immune-related adverse events (irAEs) — colitis, pneumonitis, dermatitis, endocrinopathies. CAR-T cell therapy: Patient's own T cells are genetically engineered to express a chimeric antigen receptor (CAR) targeting cancer cells. Approved for B-cell ALL (tisagenlecleucel/Kymriah — anti-CD19) and DLBCL (axicabtagene ciloleucel/Yescarta).
| Drug | Target | Cancer Type | Mechanism |
|---|---|---|---|
| Imatinib (Gleevec) | BCR-ABL, c-KIT | CML, GIST | Tyrosine kinase inhibitor |
| Gefitinib (Iressa) | EGFR | NSCLC (EGFR-mutated) | EGFR inhibitor |
| Trastuzumab (Herceptin) | HER2/neu | HER2+ breast cancer | Monoclonal antibody + ADCC |
| Vemurafenib | BRAF V600E | Melanoma | Kinase inhibitor |
| Pembrolizumab (Keytruda) | PD-1 | Melanoma, NSCLC, many others | Checkpoint inhibitor |
| Ipilimumab (Yervoy) | CTLA-4 | Melanoma | Checkpoint inhibitor |
| Olaparib (Lynparza) | PARP | BRCA-mutated ovarian/breast cancer | PARP inhibitor (synthetic lethality) |
Transplantation is the transfer of cells, tissues, or organs from one site to another. The immune system recognises transplanted tissues as foreign (unless perfectly matched), leading to graft rejection. The major histocompatibility complex (MHC) — called HLA (Human Leukocyte Antigen) in humans — is the primary determinant of transplant compatibility.
Types of grafts:
Autograft: Transplant from one site to another in the same individual (e.g., skin grafts in burn patients, bone grafts, saphenous vein grafts in coronary bypass). No immune rejection — recognised as "self".
Isograft (Syngeneic graft): Transplant between genetically identical individuals (identical twins). No immune rejection — genetically identical.
Allograft (Homograft): Transplant between genetically different individuals of the same species (e.g., kidney, heart, liver transplant). Most common type. Recipient's immune system recognises donor HLA molecules as foreign → graft rejection. Requires HLA matching and immunosuppression.
Xenograft (Heterograft): Transplant between different species (e.g., pig heart valves to humans). Faces hyperacute rejection due to pre-existing antibodies against galactose-α-1,3-galactose epitopes on pig tissues. Genetically modified pigs are being developed to overcome this.
Graft rejection mechanisms: Hyperacute rejection: Occurs within minutes to hours — pre-existing antibodies bind to donor endothelial antigens → complement activation → thrombosis. Prevented by ABO matching and cross-matching. Acute rejection (HVGR — Host vs Graft): Occurs within days to weeks — T cell-mediated (CD8+ CTLs) and antibody-mediated attack on the graft. Managed by immunosuppressive drugs. Chronic rejection: Occurs over months to years — fibrosis, vessel occlusion (transplant vasculopathy), gradual graft loss. Difficult to treat.
Graft vs Host Disease (GVHD): Occurs when donor immune cells (in bone marrow or stem cell transplants) recognise recipient tissues as foreign and attack them. Recipient is immunocompromised and cannot reject donor cells. Acute GVHD (within 100 days) affects skin (rash), liver (jaundice), and gut (diarrhoea). Chronic GVHD (after 100 days) resembles autoimmune disease. Prevention: T-cell depletion, immunosuppression (methotrexate, cyclosporine), HLA matching.
Immunosuppression in transplantation: Calcineurin inhibitors: Cyclosporine (from Trichoderma polysporum), Tacrolimus — inhibit T-cell activation by blocking calcineurin → prevent IL-2 production. Antiproliferatives: Azathioprine, Mycophenolate mofetil — block lymphocyte proliferation. Corticosteroids: Prednisolone — broad anti-inflammatory. Antibody-based: Muromonab-CD3 (OKT3 — anti-CD3 mAb), Basiliximab (anti-IL-2 receptor mAb), Anti-thymocyte globulin (ATG). HLA matching focuses on HLA-A, HLA-B, HLA-DR loci. A "full match" (6/6) between siblings gives best outcomes.
HLA System: MHC in humans is located on chromosome 6. Class I HLA (A, B, C) — on all nucleated cells, recognised by CD8+ T cells. Class II HLA (DP, DQ, DR) — on antigen-presenting cells, recognised by CD4+ T cells. High polymorphism of HLA genes makes finding matched unrelated donors challenging. Chance of full siblings sharing identical HLA haplotypes is 25%.
| Graft Type | Definition | Immune Rejection | Example |
|---|---|---|---|
| Autograft | Same individual (self to self) | None — recognised as self | Skin graft, bone graft, vein graft |
| Isograft (Syngeneic) | Genetically identical individuals | None — genetically identical | Identical twin kidney transplant |
| Allograft (Homograft) | Same species, different genetics | Yes — HVGR (acute/chronic) | Kidney, heart, liver transplant |
| Xenograft (Heterograft) | Different species | Yes — hyperacute rejection | Pig heart valves, porcine islets |
Drug abuse is the harmful use of psychoactive substances. The most commonly abused substances in India: (1) Opioids (heroin, morphine, codeine) — derived from opium poppy (Papaver somniferum). Heroin (brown sugar, smack) is diacetylmorphine — highly addictive, snorted or injected. (2) Cannabinoids — from Cannabis sativa (marijuana, hashish, ganja, charas). THC (tetrahydrocannabinol) is the active compound — affects mood, perception, appetite. (3) Cocaine — from coca plant (Erythroxylum coca) — central nervous system stimulant, highly addictive ("crack" is the freebase form). (4) Hallucinogens — LSD (lysergic acid diethylamide), mescaline (peyote cactus), psilocybin (magic mushrooms) — alter perception and mood. (5) Amphetamines — synthetic stimulants (speed, ecstasy/MDMA). (6) Barbiturates, benzodiazepines — sedatives (tranquillisers). (7) Tobacco — nicotine, tar, carbon monoxide — associated with lung cancer, COPD, cardiovascular disease. (8) Alcohol — legal, but excessive use causes cirrhosis, pancreatitis, dependence.
Dependence: Psychological (craving) and physical (withdrawal symptoms — nausea, tremors, seizures) occur when the substance is stopped. Tolerance: Need for increasing doses to achieve the same effect. Treatment: De-addiction centres (counselling, CBT), pharmacotherapy (methadone for heroin, bupropion for tobacco), 12-step programmes (Narcotics Anonymous), family and community support. The NDPS Act (1985) in India prohibits the manufacture, sale, and use of narcotic drugs and psychotropic substances except for medical purposes.
Opioids: Morphine (from opium poppy — Papaver somniferum) — used medically as a potent painkiller (analgesic) but highly addictive. Heroin (smack, diacetylmorphine) — made from morphine, more potent, causes intense euphoria followed by severe depression, physical dependence develops within weeks. Withdrawal: severe pain, diarrhoea, vomiting, muscle cramps. Cannabinoids: Marijuana/bhang/ganja/charas/hashish — all from Cannabis sativa. Active compound: THC (delta-9-tetrahydrocannabinol). Causes altered perception, increased heart rate, impaired coordination, and in chronic users, reduced motivation (amotivational syndrome). Cocaine: From leaves of Erythroxylum coca. Blocks dopamine reuptake in the brain's reward pathway, producing intense euphoria followed by severe depression. Crack cocaine is the smokable, more addictive form. Withdrawal: severe depression, fatigue, paranoia. Hallucinogens: LSD (Lysergic Acid Diethylamide — from ergot fungus, discovered by Albert Hofmann) — alters sensory perception, causes hallucinations even in tiny doses (micrograms). Mescaline (from peyote cactus), Psilocybin (from magic mushrooms). Barbiturates and Benzodiazepines: CNS depressants used as sedatives and tranquillisers — highly addictive, dangerous when combined with alcohol. Tobacco: Contains nicotine (addictive stimulant) — causes lung cancer (leading cause of cancer deaths worldwide), COPD, emphysema, heart disease, stroke, oral cancer, and pregnancy complications. Tobacco kills nearly 8 million people annually worldwide. Alcohol: CNS depressant — initially reduces inhibition, then impairs coordination, judgement, and consciousness. Long-term effects: liver cirrhosis (scarring of liver), hepatitis, pancreatitis, brain damage (Wernicke-Korsakoff syndrome), heart disease, addiction. Foetal alcohol syndrome in children of mothers who drink during pregnancy.
| Category | Source | Examples | Effects |
|---|---|---|---|
| Opioids | Papaver somniferum | Morphine, Heroin, Codeine | Pain relief, euphoria, addiction, respiratory depression |
| Cannabinoids | Cannabis sativa | Marijuana, Hashish, Ganja, Charas | Altered perception, increased heart rate, impaired memory |
| Cocaine | Erythroxylum coca | Cocaine, Crack cocaine | Intense euphoria, then depression, paranoia, cardiac risk |
| Hallucinogens | Ergot fungus, cactus, mushrooms | LSD, Mescaline, Psilocybin | Altered sensory perception, hallucinations, psychosis |
| Barbiturates | Synthetic | Phenobarbital, Pentobarbital | CNS depression, sedation, addiction, overdose risk |
| Nicotine | Nicotiana tabacum | Cigarettes, chewing tobacco, gutka | Stimulant, addiction, lung cancer, heart disease, COPD |
| Alcohol | Fermentation | Ethanol in beverages | CNS depression, liver cirrhosis, brain damage, addiction |
Prevention of drug abuse: Education about harmful effects, counselling, building self-esteem, healthy recreational alternatives, avoiding peer pressure, parental guidance and communication. Treatment: De-addiction programmes (medical + psychological support), rehabilitation centres, pharmacotherapy (methadone for heroin addiction, nicotine patches for tobacco), and support groups (Alcoholics Anonymous, Narcotics Anonymous). The NDPS Act (1985) in India restricts and regulates drug use, with severe penalties for trafficking. The "Just Say No" campaign and school-based education programmes aim at primary prevention. COTPA (Cigarettes and Other Tobacco Products Act, 2003) prohibits smoking in public places and advertising of tobacco products in India.
Microbes (bacteria, fungi, protozoa, viruses) are not always harmful — they play crucial beneficial roles in human welfare, industry, and the environment.
Microbes have been used for thousands of years in food preparation, long before the discovery of their existence. Common household products made using microbes:
Curd/Yoghurt: Lactobacillus (bacteria) and Lactobacillus bulgaricus + Streptococcus thermophilus ferment lactose to lactic acid, coagulating milk proteins. Curd can be used to inoculate fresh milk to make more curd (traditional practice). Bread, Idli, Dosa: Saccharomyces cerevisiae (baker's yeast) produces CO2 that causes dough/batter to rise. The ethanol produced evaporates during baking/cooking. Cheese: Penicillium roqueforti gives Roquefort cheese its blue veins and sharp flavour. Penicillium camemberti gives Camembert its soft, creamy texture and white rind. Swiss cheese has large holes caused by Propionibacterium shermanii which produces CO2 during ripening. Vinegar: Acetobacter aceti oxidises ethanol in fermented liquids (wine, cider) to acetic acid. Used as a preservative and condiment. Fermented foods: Soy sauce (fermented by Aspergillus oryzae — koji mould — and Lactobacillus + yeast in brine), Tofu (soybean curd — Mucor species used to ferment soybeans in some varieties), Sauerkraut (cabbage fermented by Leuconostoc and Lactobacillus species in salt brine), Kimchi (Korean fermented vegetables), Natto (fermented soybeans by Bacillus subtilis — rich in vitamin K2), Tempeh (fermented soybeans by Rhizopus oligosporus — a fungus). Pickles (vegetables preserved in brine where natural Lactobacillus fermentation produces acid that preserves them).
Microbes are used in large-scale industrial fermentation to produce a wide range of products valuable to humans. The choice of microbe depends on the desired product and optimal fermentation conditions (temperature, pH, aeration, nutrient availability).
Alcoholic beverages: Saccharomyces cerevisiae (brewer's/baker's yeast) ferments sugars to ethanol and CO2. Wine is made by fermenting grape juice. Beer uses barley malt (sprouted barley grains) fermented by yeast, with hops added for bitterness and flavour. Distilled spirits (whisky, rum, brandy, vodka, gin) are produced by distilling the fermented liquid to concentrate ethanol. In India, Mahua flowers and Toddy (from palm sap) are traditional fermented beverages.
| Product | Microbe | Type | Application |
|---|---|---|---|
| Penicillin | Penicillium notatum | Fungus | Antibiotic — kills gram-positive bacteria |
| Streptomycin | Streptomyces griseus | Bacterium | Antibiotic — TB treatment |
| Tetracycline | Streptomyces aureofaciens | Bacterium | Broad-spectrum antibiotic |
| Erythromycin | Streptomyces erythraeus | Bacterium | Antibiotic — respiratory infections |
| Cyclosporin A | Trichoderma polysporum | Fungus | Immunosuppressant — organ transplants |
| Statins | Monascus purpureus | Yeast/Fungus | Cholesterol-lowering drug |
| Citric acid | Aspergillus niger | Fungus | Food acidulant, preservative |
| Lactic acid | Lactobacillus spp. | Bacterium | Food preservative, plastics |
| Glutamic acid (MSG) | Corynebacterium glutamicum | Bacterium | Flavour enhancer |
| Vitamin B12 | Pseudomonas denitrificans | Bacterium | Vitamin supplement |
| Streptokinase | Streptococcus spp. | Bacterium | Clot buster — heart attack treatment |
| Lipase | Candida rugosa | Yeast | Detergent additive — removes oily stains |
| Pectinase | Aspergillus niger | Fungus | Fruit juice clarification |
| Dextran | Leuconostoc mesenteroides | Bacterium | Blood plasma substitute |
| Ethanol | Saccharomyces cerevisiae | Yeast | Fuel, beverages, solvent |
Sewage (municipal waste water) contains organic matter, pathogens, and suspended solids that must be removed before the water can be released into natural water bodies. The treatment process involves multiple stages:
Primary treatment: Physical process — sewage is passed through screens and grit chambers to remove large objects (rags, sticks, plastic), then enters sedimentation tanks where suspended solids settle as sludge and oils/grease float to the surface (skimming). Removes about 50-60% of suspended solids.
Secondary treatment (Biological): The effluent from primary treatment enters aeration tanks where air is bubbled through the liquid. Aerobic microbes (bacteria, fungi, protozoa) grow and form flocs (masses of microbes held together by slime layers). These microbes consume organic matter (BOD reduction). After aeration, the mixture enters a settling tank where the microbial flocs settle as activated sludge. Some sludge is recycled to maintain the microbial population in the aeration tank. The remaining sludge is transferred to an anaerobic digester. The clarified effluent (treated water) is disinfected (chlorinated or UV treated) before being released into rivers or reused for irrigation. The activated sludge process reduces BOD (Biochemical Oxygen Demand) by 90-95%.
Sludge treatment: The settled sludge is digested anaerobically by methanogenic bacteria (Methanobacterium) in a closed digester tank. This produces biogas (methane) which can be used as fuel. The remaining digested sludge is used as fertiliser (rich in nutrients). BOD: Amount of oxygen (in mg/L) required by aerobic microbes to decompose organic matter in a water sample over 5 days at 20°C. High BOD = high organic pollution. Clean water has BOD < 5 mg/L; raw sewage has BOD of 200-600 mg/L. BOD is a key parameter for assessing water quality and treatment efficiency.
Biogas is a clean, renewable fuel produced by the anaerobic digestion of organic matter. Composition: Methane (CH4: 50-70%), Carbon dioxide (CO2: 30-40%), Hydrogen (H2: 1-5%), Hydrogen sulphide (H2S: traces). Biogas is produced by the action of methanogenic bacteria (Methanobacterium, Methanococcus, Methanosarcina) — these are archaebacteria found naturally in marshes, swamps, and the gut of ruminant animals (cows, buffaloes).
Biogas plant: A typical biogas plant (e.g., Gobar gas plant) has: (1) Mixing tank — cow dung and water are mixed into a slurry. (2) Digester — a sealed, underground concrete tank where anaerobic digestion occurs. The slurry remains for about 40-50 days. (3) Gas holder — a movable steel or fibreglass dome that collects the biogas produced. (4) Outlet — the spent slurry (rich in nutrients) flows out and is used as fertiliser. (5) Gas pipe — connects to stoves, lamps, or generators. A family-sized plant (2-4 m3 gas/day) requires about 25-50 kg of cow dung daily. Benefits: clean fuel (reduces smoke indoors), fertiliser from slurry, waste disposal, reduces deforestation (less wood burning), and reduces greenhouse gas emissions (methane is captured rather than released from open manure pits).
Using natural predators/pathogens to control pests, avoiding chemical pesticides. Bacillus thuringiensis (Bt): Produces a toxin (Bt toxin) that kills insect larvae (used in Bt cotton — a GM crop, but the lesson here is the natural microbe itself). Trichoderma: A fungus used as a biocontrol agent against soil-borne plant pathogens. Nucleopolyhedrovirus (NPV): A virus that infects insects; species-specific, does not harm non-target organisms. Ladybird beetles and Dragonflies are also used but are not microbes — they are biological control agents in general. The concept of biological control is ecologically sustainable and avoids the environmental damage caused by chemical pesticides.
Living microorganisms that enrich soil nutrients. Rhizobium: Symbiotic nitrogen-fixing bacteria in root nodules of legumes (converts atmospheric N2 to usable forms). Azospirillum and Azotobacter: Free-living nitrogen-fixing bacteria (Azotobacter in soil, Azospirillum associated with grass roots). Cyanobacteria (Blue-green algae): Nostoc, Anabaena, Oscillatoria — fix atmospheric nitrogen in waterlogged rice paddies. Azolla (a water fern) has Anabaena azollae in its leaves and is used as a green manure in rice cultivation. Mycorrhiza (fungus-root association): Helps in phosphorus uptake from soil. Biofertilisers are cost-effective, eco-friendly, and reduce the need for chemical fertilisers.
| Feature | Biocontrol Agents | Biofertilisers |
|---|---|---|
| Function | Control pests and pathogens | Enrich soil nutrients |
| Examples | Bt (Bacillus thuringiensis), Trichoderma, NPV | Rhizobium, Azospirillum, Azotobacter, Cyanobacteria, Mycorrhiza |
| Target | Insect larvae, soil pathogens | Plants (enhance nutrient uptake) |
| Mechanism | Toxin production, parasitism, competition | Nitrogen fixation, phosphate solubilisation, nutrient mobilisation |
| Environmental impact | Reduces chemical pesticide use | Reduces chemical fertiliser use |
| Economic benefit | Cost-effective, sustainable | Cost-effective, improves soil health |
Industrial fermentation involves the large-scale cultivation of microorganisms to produce valuable products. Understanding fermentation kinetics is crucial for optimising yield and productivity.
Fermentation kinetics: Microbial growth in a closed system (batch culture) follows distinct phases: Lag phase — microbes adapt to the new environment, synthesising enzymes needed for substrate utilisation (no net growth). Log (exponential) phase — cells divide at a constant maximum rate (μ_max, the specific growth rate). Nutrients are abundant, waste products are minimal. Stationary phase — growth rate equals death rate due to nutrient depletion and accumulation of toxic metabolites (ethanol, organic acids). This is when secondary metabolites (antibiotics, statins) are often produced — the idophase (trophophase = growth phase, idophase = production phase). Death phase — number of viable cells declines exponentially. Key parameters: Specific growth rate (μ, h⁻¹), doubling time (t_d = ln2/μ), substrate utilisation rate, product yield (Y_p/s = g product/g substrate consumed), and productivity (g product/L/h).
Batch Fermentation: All nutrients are added at the beginning in a closed vessel. Microbes grow through all phases. Simple, low risk of contamination, flexible. Disadvantages: Low productivity due to downtime between batches (cleaning, sterilisation, re-inoculation), substrate inhibition at high initial concentrations, variable product quality between batches. Used for: High-value products (antibiotics — penicillin), enzymes, speciality chemicals.
Continuous Fermentation: Fresh nutrients are continuously added and culture fluid is continuously removed at the same rate (steady-state conditions). The system maintains cells in log phase (constant growth rate) by controlling dilution rate. Advantages: Higher productivity (no downtime), consistent product quality, better control of growth conditions. Disadvantages: Higher risk of contamination (long operation), strain degeneration (mutants may take over), complex control systems required. Used for: Single-cell protein production, ethanol production (some processes), waste treatment.
Fed-batch Fermentation: Nutrients are added incrementally during the process, but culture is not removed until the end. Combines advantages of batch and continuous — avoids substrate inhibition, allows high cell density, extends production phase. Commonly used for penicillin production — glucose is fed continuously to maintain optimal concentration without causing catabolite repression (high glucose represses penicillin synthesis).
| Feature | Batch | Continuous | Fed-Batch |
|---|---|---|---|
| Nutrient addition | All at start | Continuous | Intermittent/incremental |
| Product removal | At end | Continuous | At end |
| Growth phases | All four phases | Steady-state (log phase maintained) | Extended log/stationary |
| Productivity | Low (downtime between batches) | High (steady operation) | Moderate to high |
| Contamination risk | Low (short runs) | High (prolonged operation) | Moderate |
| Control complexity | Simple | Complex (dilution rate, sensors) | Moderate (feed rate control) |
| Best for | High-value products, small scale | Low-value products, large scale | Products with catabolite repression (penicillin) |
A bioreactor (or fermenter) is a vessel designed to provide optimal conditions for microbial growth and product formation. Key features: (1) Agitation system — impellers (Rushton turbine) for mixing and mass transfer. (2) Aeration system — sparger (ring with holes) to introduce sterile air. (3) Temperature control — cooling jacket or internal coils. (4) pH control — acid/base addition via pumps. (5) Sensors — for temperature, pH, dissolved oxygen (DO), foam detection. (6) Sterile ports — for inoculation, sampling, and addition of nutrients. (7) Foam control — foam breaker or antifoam addition. (8) Computer control system (SCADA) for monitoring and automation.
Immobilised enzymes: Enzymes that are attached to an inert support material (matrix) to allow re-use and continuous operation. Advantages: Reusability (reduces cost), increased stability (heat, pH, organic solvents), easier product recovery (enzyme separated from product), continuous processing in packed-bed reactors. Methods of immobilisation: (1) Adsorption — physical binding to a solid support (activated charcoal, silica, alumina) via weak forces (van der Waals, ionic). Simple but reversible. (2) Covalent bonding — chemical bonds between enzyme and support (agarose, cellulose, polyacrylamide). Strong binding, not reversible. (3) Entrapment — enzymes are trapped in a gel matrix (alginate beads, polyacrylamide gel, silica sol-gel). Substrate and product diffuse in/out. (4) Encapsulation — enzymes are enclosed in semi-permeable membranes (microcapsules, liposomes). (5) Cross-linking — enzymes are cross-linked to each other (CLEAs — Cross-Linked Enzyme Aggregates) using glutaraldehyde. Applications: Immobilised glucose isomerase (production of high-fructose corn syrup — the largest industrial use of immobilised enzymes), immobilised penicillin acylase (production of semi-synthetic penicillins), immobilised lipases (biodiesel production), immobilised lactase (lactose-free milk), immobilised aminoacylase (production of L-amino acids), biosensors (glucose sensor using immobilised glucose oxidase).
Penicillin, the first antibiotic discovered (Fleming, 1928), is produced industrially by large-scale fermentation using Penicillium chrysogenum (a higher-yielding strain than P. notatum). The production process involves the following steps:
Step 1 — Strain improvement: Wild-type P. chrysogenum produces very low levels of penicillin. Strain improvement is done by mutation (UV radiation, chemical mutagens like NTG) and selection — modern strains produce >50,000 times more penicillin than Fleming's original isolate. Genetic engineering has also been used to introduce additional copies of biosynthetic gene clusters.
Step 2 — Inoculum preparation: A pure culture of the selected strain is grown in shake flasks to produce a seed culture. The seed culture is then transferred to larger seed fermenters to build up sufficient biomass for inoculation of the production fermenter (typically 5-10% v/v inoculum).
Step 3 — Production fermentation: The production fermenter (100,000-200,000 L capacity) contains a complex medium with: Carbon source (lactose or glucose — glucose is fed slowly to avoid catabolite repression), Nitrogen source (corn steep liquor — a byproduct of corn processing, rich in amino acids and nitrogen), Precursor (phenylacetic acid or phenoxyacetic acid — incorporated into the penicillin side chain), and minerals (phosphate, magnesium, sulfate). Fermentation conditions: Temperature 25-27°C, pH 6.5-6.8, dissolved oxygen maintained at >30% saturation by aeration (0.5-1 vvm) and agitation. Fermentation lasts 5-7 days in fed-batch mode.
Step 4 — Penicillin is a secondary metabolite: It is produced during the stationary (idophase) phase, not during active growth (trophophase). As glucose is depleted and growth slows, the fungus enters the production phase where penicillin biosynthetic enzymes are activated. Continuous feeding of glucose (fed-batch) maintains the culture in a prolonged production phase.
Step 5 — Recovery and purification: After fermentation, the broth is filtered to remove mycelial biomass (fungal cells). The filtrate (containing penicillin) is cooled to 0-5°C and acidified (pH 2.0-2.5) with phosphoric acid. Penicillin (an organic acid) is extracted into an organic solvent (amyl acetate or butyl acetate) by liquid-liquid extraction at low pH. The organic phase is separated and penicillin is back-extracted into a neutral aqueous buffer at pH 7.0-7.5. The buffer solution is treated with activated charcoal to remove impurities. Penicillin is crystallised by adjusting pH and adding suitable solvents. Crystals are washed, dried, and packaged under sterile conditions.
Step 6 — Semi-synthetic penicillins: Natural penicillin (Penicillin G — benzylpenicillin) can be modified to produce semi-synthetic penicillins with improved properties. The enzyme penicillin acylase (or chemical hydrolysis) removes the side chain to produce 6-APA (6-aminopenicillanic acid). Different side chains are then attached chemically to produce: Amoxicillin (broader spectrum, oral), Ampicillin (broader spectrum, oral/injectable), Methicillin (penicillinase-resistant — but now MRSA has evolved), Piperacillin (anti-pseudomonal). Semi-synthetic penicillins overcome limitations of natural penicillin: narrow spectrum, acid lability (destroyed by stomach acid — penicillin V is acid-stable), and susceptibility to β-lactamases.
Adolescence (10-19 years) is a critical period of physical, mental, and social development. Reproductive health education during this period is essential for: (1) Awareness about physical changes during puberty (secondary sexual characteristics, menarche, spermarche). (2) Knowledge about reproductive system and process. (3) Information about contraception, STDs, and safe sex practices. (4) Prevention of unwanted pregnancies and unsafe abortions. (5) Building healthy relationships and respect for the opposite sex. (6) Avoiding drug and alcohol abuse. The Government of India's RCH (Reproductive and Child Health Care) programme, launched in 1997, aims to provide comprehensive reproductive health services including family planning, maternal and child health, adolescent health, and STD/HIV prevention. WHO defines reproductive health as a state of complete physical, mental, and social well-being in all matters relating to the reproductive system.
India was the first country in the world to launch a national family planning programme (1952). The goal is to stabilise the population at a level consistent with sustainable economic development. India's population has grown from 361 million (1951) to over 1.4 billion (2023) — a fourfold increase. Family planning methods include natural methods (rhythm method, withdrawal, lactational amenorrhea), barrier methods (condoms, diaphragms), IUDs, oral contraceptives, injectables, implants, and sterilisation (vasectomy, tubectomy). The total fertility rate (TFR) in India has declined from 6.0 (1951) to about 2.0 (2023) — approaching replacement level (2.1). States like Kerala and Tamil Nadu have achieved replacement level fertility. The government promotes the "small family norm" through incentives, awareness campaigns, and free contraceptive distribution. Family planning not only controls population but also improves maternal and child health by preventing high-risk pregnancies and reducing infant mortality.
Malaria is caused by four species of Plasmodium: P. vivax (benign tertian malaria — fever every 48 hours), P. falciparum (malignant tertian — most severe, fever irregular, cerebral malaria), P. malariae (quartan malaria — fever every 72 hours), P. ovale (rare). Life cycle involves two hosts:
In female Anopheles mosquito (definitive host): Sexual reproduction occurs. When the mosquito bites an infected person, it ingests gametocytes (male and female) from the blood. In the mosquito's gut, gametocytes fuse to form a zygote → ookinete → oocyst → sporozoites (infective stage). Sporozoites migrate to the salivary glands.
In humans (intermediate host): (1) Sporozoites are injected when an infected mosquito bites. (2) They travel via bloodstream to the liver (hepatic stage) and invade hepatocytes. (3) In the liver, they multiply asexually (exo-erythrocytic schizogony) producing thousands of merozoites. (4) Merozoites burst out of liver cells and invade red blood cells (erythrocytic stage). (5) In RBCs, they grow and multiply (erythrocytic schizogony), rupturing RBCs and releasing more merozoites — this rupture causes the characteristic periodic fevers (chills and fever spikes). (6) Some merozoites differentiate into gametocytes (sexual stage) which can be picked up by another mosquito. Diagnosis: Blood smear examination (Gold standard) — thick and thin smears stained with Giemsa stain. Rapid diagnostic tests (RDTs) detect Plasmodium antigens. Treatment: Chloroquine (first-line for uncomplicated malaria), Artemisinin-based Combination Therapy (ACT — for drug-resistant P. falciparum), Primaquine (to prevent relapse in P. vivax by killing hypnozoites in the liver). Prevention: Mosquito control (insecticide-treated bed nets, indoor residual spraying), chemoprophylaxis for travellers, eliminating mosquito breeding sites (stagnant water).
STDs are infections transmitted primarily through sexual contact. Common STDs: Gonorrhoea (Neisseria gonorrhoeae — bacterium), Syphilis (Treponema pallidum — spirochaete bacterium), Chlamydiasis (Chlamydia trachomatis — intracellular bacterium), Trichomoniasis (Trichomonas vaginalis — protozoan), Genital herpes (Herpes simplex virus — HSV, viral), Genital warts (Human papillomavirus — HPV, viral), Hepatitis B (HBV — viral, also transmitted sexually), HIV/AIDS (retrovirus). Most STDs are curable except HIV, Hepatitis B, and genital herpes (can be managed but not cured). Prevention: Awareness, safe sex (condoms), avoiding multiple partners, prompt treatment, vaccination (HPV vaccine prevents cervical cancer and genital warts; Hepatitis B vaccine). STDs in early stages are asymptomatic in many cases — especially in women — making early detection difficult. If untreated, STDs can lead to: pelvic inflammatory disease (PID), infertility, ectopic pregnancy, cervical cancer (HPV), stillbirth, neonatal infections, and increased risk of HIV transmission. Diagnosis involves microscopic examination, serological tests (VDRL for syphilis), culture, and PCR-based molecular tests.
Antimicrobial resistance occurs when microorganisms (bacteria, fungi, viruses, parasites) develop the ability to survive exposure to drugs that previously killed them or inhibited their growth. This is a natural evolutionary process, but it is accelerated by the misuse and overuse of antimicrobial drugs in humans, animals, and agriculture. AMR is one of the top global public health threats — it is estimated that by 2050, 10 million deaths per year could be attributable to AMR (more than cancer). Mechanisms of resistance: (1) Enzymatic inactivation — bacteria produce enzymes that destroy the drug (e.g., β-lactamases destroy penicillin — ESBL-producing bacteria are resistant to most β-lactam antibiotics). (2) Target modification — bacteria alter the drug's target site (e.g., MRSA — methicillin-resistant Staphylococcus aureus has altered PBP protein). (3) Efflux pumps — bacteria pump the drug out of the cell before it can act. (4) Reduced permeability — bacteria reduce drug entry through porins (e.g., carbapenem resistance in Pseudomonas aeruginosa). (5) Biofilm formation — bacteria form a protective matrix that prevents drug penetration. Contributing factors: Over-prescription of antibiotics, incomplete courses of treatment (bacteria survive and develop resistance), use of antibiotics in animal feed (growth promotion), lack of new drug development, poor infection control in hospitals (HAI — hospital-acquired infections). Solutions: Antibiotic stewardship (rational prescribing), completing full courses, developing new antibiotics, vaccination (prevents infections and reduces antibiotic use), improved hygiene and sanitation, infection prevention and control, limiting antibiotic use in agriculture. The WHO Global Action Plan on AMR (2015) calls for coordinated action across all sectors. India launched the National Action Plan on Antimicrobial Resistance (NAP-AMR) in 2017.
| Disease | Pathogen | Type | Transmission |
|---|---|---|---|
| Malaria | Plasmodium vivax/falciparum | Protozoan | Female Anopheles mosquito |
| Tuberculosis | Mycobacterium tuberculosis | Bacterial | Airborne droplets |
| AIDS | HIV (Human Immunodeficiency Virus) | Viral (Retrovirus) | Sexual, blood, needles, mother-to-child |
| Typhoid | Salmonella typhi | Bacterial | Contaminated food/water (Widal test) |
| Pneumonia | Streptococcus pneumoniae | Bacterial | Airborne droplets (alveoli fill with fluid) |
| Common cold | Rhinovirus | Viral | Airborne droplets |
| Dengue | Dengue virus (Flavivirus) | Viral | Aedes aegypti mosquito |
| Chikungunya | CHIKV (Togavirus) | Viral | Aedes aegypti mosquito |
| Ringworm | Trichophyton, Microsporum | Fungal | Direct contact with infected surfaces |
| Filariasis | Wuchereria bancrofti | Helminth | Mosquito (Culex) |
| Ascariasis | Ascaris lumbricoides | Helminth | Contaminated food/water (roundworm) |
| Amoebiasis | Entamoeba histolytica | Protozoan | Contaminated food/water (bloody diarrhoea) |
| Kala-azar | Leishmania donovani | Protozoan | Sandfly |
| Gonorrhoea | Neisseria gonorrhoeae | Bacterial (STD) | Sexual contact |
| Syphilis | Treponema pallidum | Bacterial (STD) | Sexual contact |
| Cell Type | Lineage | Function |
|---|---|---|
| Neutrophil | Granulocyte (myeloid) | Phagocytosis — most abundant WBC, first responder, kills bacteria via NETs and ROS |
| Macrophage | Monocyte (myeloid) | Phagocytosis, antigen presentation, cytokine secretion, tissue repair |
| Dendritic cell | Myeloid | Most potent antigen-presenting cell (APC) — links innate and adaptive immunity |
| Natural Killer (NK) cell | Lymphocyte (innate) | Kills virus-infected cells and tumour cells without prior sensitisation |
| B-lymphocyte | Lymphocyte (adaptive) | Produces antibodies (humoral immunity), differentiates into plasma cells and memory B cells |
| T-helper cell (CD4+) | Lymphocyte (adaptive) | Activates B cells, T cells, and macrophages — "master regulators" of immune response |
| T-cytotoxic cell (CD8+) | Lymphocyte (adaptive) | Kills infected cells (cell-mediated immunity) — recognises MHC Class I + antigen |
| Regulatory T cell (Treg) | Lymphocyte (adaptive) | Suppresses immune response — prevents autoimmunity and excessive inflammation |
| Mast cell | Granulocyte (myeloid) | Releases histamine in allergic reactions — has IgE receptors, involved in inflammation |
| Eosinophil | Granulocyte (myeloid) | Fights parasitic infections (helminths), involved in allergic inflammation |
| Basophil | Granulocyte (myeloid) | Releases histamine and heparin in allergic reactions — least abundant WBC |
| Product | Microbe | Use |
|---|---|---|
| Penicillin | Penicillium notatum | Antibiotic |
| Streptomycin | Streptomyces griseus | Antibiotic (TB) |
| Cyclosporin A | Trichoderma polysporum | Immunosuppressant |
| Statins | Monascus purpureus | Cholesterol-lowering |
| Citric acid | Aspergillus niger | Food acidulant |
| Ethanol | Saccharomyces cerevisiae | Fuel, beverages |
| Streptokinase | Streptococcus | Clot buster |
| Lipase | Candida rugosa | Detergent additive |